Clinical Trials Browser

Phase 2 × OTHER × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Clear all

NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma